FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction Cancer
Vyloy is the first and only CLDN18.2-targeted therapy approved in the United States
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.